• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

变构调节剂的发现:从偶然发现到基于结构的设计。

Allosteric Modulator Discovery: From Serendipity to Structure-Based Design.

机构信息

Key Laboratory of Cell Differentiation and Apoptosis of Chinese Ministry of Education, Clinical and Fundamental Research Center, Renji Hospital , Shanghai Jiao-Tong University School of Medicine , Shanghai 200025 , China.

Medicinal Bioinformatics Center , Shanghai Jiao-Tong University School of Medicine , Shanghai 200025 , China.

出版信息

J Med Chem. 2019 Jul 25;62(14):6405-6421. doi: 10.1021/acs.jmedchem.8b01749. Epub 2019 Mar 7.

DOI:10.1021/acs.jmedchem.8b01749
PMID:30817889
Abstract

Allosteric modulators bound to structurally diverse allosteric sites can achieve better pharmacological advantages than orthosteric ligands. The discovery of allosteric modulators, however, has been traditionally serendipitous, owing to the complex nature of allosteric modulation. Recent advances in the understanding of allosteric regulatory mechanisms and remarkable availability of structural data of allosteric proteins and modulators, as well as their complexes, have greatly contributed to the development of various computational approaches to guide the structure-based discovery of allosteric modulators. This Perspective first outlines the evolution of the allosteric concept and describes the advantages and hurdles facing allosteric modulator discovery. The current available computational approaches, together with experimental approaches aiming to highlight allosteric studies, are then highlighted, emphasizing successful examples with their combined applications. We aimed to increase the awareness of the feasibility of the structure-based discovery of allosteric modulators using an integrated computational and experimental paradigm.

摘要

变构调节剂与结构多样的变构位点结合,可以比正位配体获得更好的药理优势。然而,由于变构调节的复杂性,变构调节剂的发现传统上是偶然的。近年来,人们对变构调节机制的理解有了很大进展,变构蛋白和调节剂及其复合物的结构数据也得到了显著的丰富,这极大地促进了各种基于结构的变构调节剂发现的计算方法的发展。本观点首先概述了变构概念的演变,并描述了变构调节剂发现所面临的优势和障碍。然后突出了当前可用的计算方法,以及旨在强调变构研究的实验方法,强调了它们的联合应用的成功例子。我们的目的是通过综合计算和实验范例,提高人们对基于结构的变构调节剂发现的可行性的认识。

相似文献

1
Allosteric Modulator Discovery: From Serendipity to Structure-Based Design.变构调节剂的发现:从偶然发现到基于结构的设计。
J Med Chem. 2019 Jul 25;62(14):6405-6421. doi: 10.1021/acs.jmedchem.8b01749. Epub 2019 Mar 7.
2
Opportunities and Challenges in the Discovery of Allosteric Modulators of GPCRs.G蛋白偶联受体变构调节剂发现中的机遇与挑战
Methods Mol Biol. 2018;1705:297-319. doi: 10.1007/978-1-4939-7465-8_13.
3
Discovery of hidden allosteric sites as novel targets for allosteric drug design.发现隐藏的变构位点作为变构药物设计的新靶点。
Drug Discov Today. 2018 Feb;23(2):359-365. doi: 10.1016/j.drudis.2017.10.001. Epub 2017 Oct 10.
4
Designed dualsteric modulators: A novel route for drug discovery.设计双立体调节剂:药物发现的新途径。
Drug Discov Today. 2024 Oct;29(10):104141. doi: 10.1016/j.drudis.2024.104141. Epub 2024 Aug 19.
5
Discovery of allosteric BCR-ABL inhibitors from phenotypic screen to clinical candidate.从表型筛选到临床候选药物:变构BCR-ABL抑制剂的发现
Methods Enzymol. 2014;548:173-88. doi: 10.1016/B978-0-12-397918-6.00007-0.
6
Strategies for the identification of allosteric modulators of G-protein-coupled receptors.G 蛋白偶联受体变构调节剂的鉴定策略。
Biochem Pharmacol. 2011 Mar 15;81(6):691-702. doi: 10.1016/j.bcp.2010.12.012. Epub 2010 Dec 22.
7
Research progress of indole-fused derivatives as allosteric modulators: Opportunities for drug development.吲哚稠合衍生物作为变构调节剂的研究进展:药物开发机遇
Biomed Pharmacother. 2023 Jun;162:114574. doi: 10.1016/j.biopha.2023.114574. Epub 2023 Mar 28.
8
Current and Future Challenges in GPCR Drug Discovery.G蛋白偶联受体药物研发中的当前与未来挑战
Methods Mol Biol. 2018;1705:1-21. doi: 10.1007/978-1-4939-7465-8_1.
9
Discovery and characterization of non-ATP site inhibitors of the mitogen activated protein (MAP) kinases.发现并鉴定有丝分裂原激活蛋白(MAP)激酶非 ATP 结合位点抑制剂。
ACS Chem Biol. 2011 Mar 18;6(3):234-44. doi: 10.1021/cb1002619. Epub 2011 Jan 20.
10
Leveraging Structural Diversity and Allosteric Regulatory Mechanisms of Protein Kinases in the Discovery of Small Molecule Inhibitors.利用蛋白激酶的结构多样性和变构调节机制发现小分子抑制剂
Curr Med Chem. 2017;24(42):4838-4872. doi: 10.2174/0929867323666161006113418.

引用本文的文献

1
Dynamic energy conversion in protein catalysis: From brownian motion to enzymatic function.蛋白质催化中的动态能量转换:从布朗运动到酶功能
Comput Struct Biotechnol J. 2025 Jul 30;27:3337-3369. doi: 10.1016/j.csbj.2025.07.050. eCollection 2025.
2
An update for AlphaFold3 versus experimental structures: assessing the precision of small molecule binding in GPCRs.AlphaFold3与实验结构的更新:评估GPCR中小分子结合的精度。
Acta Pharmacol Sin. 2025 Jul 9. doi: 10.1038/s41401-025-01617-4.
3
Role of artificial intelligence in revolutionizing drug discovery.
人工智能在变革药物研发中的作用。
Fundam Res. 2024 May 9;5(3):1273-1287. doi: 10.1016/j.fmre.2024.04.021. eCollection 2025 May.
4
Can Deep Learning Blind Docking Methods be Used to Predict Allosteric Compounds?深度学习盲对接方法可用于预测变构化合物吗?
J Chem Inf Model. 2025 Apr 14;65(7):3737-3748. doi: 10.1021/acs.jcim.5c00331. Epub 2025 Apr 1.
5
The Evolving Landscape of Protein Allostery: From Computational and Experimental Perspectives.蛋白质变构的演变态势:从计算和实验视角看
J Mol Biol. 2025 Mar 4:169060. doi: 10.1016/j.jmb.2025.169060.
6
Exploring the constitutive activation mechanism of the class A orphan GPR20.探索A类孤儿GPR20的组成性激活机制。
Acta Pharmacol Sin. 2025 Feb;46(2):500-511. doi: 10.1038/s41401-024-01385-7. Epub 2024 Sep 10.
7
Unveiling Allosteric Regulation and Binding Mechanism of BRD9 through Molecular Dynamics Simulations and Markov Modeling.通过分子动力学模拟和马尔可夫建模揭示 BRD9 的别构调节和结合机制。
Molecules. 2024 Jul 25;29(15):3496. doi: 10.3390/molecules29153496.
8
3-chymotrypsin-like protease in SARS-CoV-2.SARS-CoV-2 中的 3-糜蛋白酶样蛋白酶。
Biosci Rep. 2024 Aug 28;44(8). doi: 10.1042/BSR20231395.
9
Discovery of novel positive allosteric modulators targeting GluN1/2A NMDARs as anti-stroke therapeutic agents.发现靶向GluN1/2A N-甲基-D-天冬氨酸受体的新型正变构调节剂作为抗中风治疗药物
RSC Med Chem. 2024 Jan 4;15(4):1307-1319. doi: 10.1039/d3md00455d. eCollection 2024 Apr 24.
10
GETdb: A comprehensive database for genetic and evolutionary features of drug targets.GETdb:一个关于药物靶点遗传和进化特征的综合数据库。
Comput Struct Biotechnol J. 2024 Apr 3;23:1429-1438. doi: 10.1016/j.csbj.2024.04.006. eCollection 2024 Dec.